Impulsive Behavior: Clinical Trials

2 trials for Impulsive Behavior, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown. 2 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 32Unknown 2
Phase 21Unknown 1

Follow Impulsive Behavior: new trials by email Literature Review of Impulsive Behavior trials Research Report on Impulsive Behavior

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation
Bupropion, Bupropion + Naltrexone - Tobacco Use Disorder
Phase 2 / Phase 3UnknownUniversity of Minnesota1202006-11-012009-12-03
Repetitive Behavior Disorders in People With Severe Mental Retardation
sertraline - Mental Retardation, Stereotyped Behavior
Phase 3UnknownEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)1992-09-012007-06-26

Narrower conditions

Behavior, Addictive (1)  ·  Compulsive Behavior (1)  ·  Intellectual Disability (1)  ·  Self-Injurious Behavior (1)  ·  Smoking (1)  ·  Stereotyped Behavior (1)  ·  Stereotypic Movement Disorder (1)  ·  Tobacco Use Disorder (1)

Broader conditions

Behavior (2)  ·  Mental Disorders (2)  ·  Behavioral Symptoms (1)  ·  Chemically-Induced Disorders (1)  ·  Compulsive Behavior (1)  ·  Nervous System Diseases (1)  ·  Neurobehavioral Manifestations (1)  ·  Neurodevelopmental Disorders (1)  ·  Neurologic Manifestations (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Signs and Symptoms (1)  ·  Substance-Related Disorders (1)

Interventions

Bupropion (1)  ·  Naltrexone (1)  ·  Sertraline (1)

Sponsors

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  University of Minnesota (1)

Countries

United States (2)

Top investigators

Marc E Mooney, Ph.D. (1)  ·  Mark Lewis, PhD (1)

Results publications

PMID 27213949

NIH funding

K01DA019446 (1)